22159-Breast Cancer-NA-1558

Breast Cancer

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)

  • Details

ClinicalTrials.gov ID: NCT05501886
Diagnosis Type: NA
USOR Number:

  • Address

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

Search by practice name, trial titles, indicators and specific disease types.